Clinical evidence
Developed and evaluated with fertility experts
T’EASY has been developed and evaluated with fertility laboratories, including comparative work with experienced operators in real embryology workflows. The figures below come from one proof-of-concept pilot. They describe that study, not a universal performance guarantee.
98%
Average share of sperm cells present that were detected in two TESE samples in the pilot (98.4% and 98.2%).
10 min
Automated analysis time reported for each sample in that comparison.
24 min
Average time taken by experienced operators for the manual comparison.
Reported from a UZ Brussel proof-of-concept pilot (November 2024; two samples, 340 and 240 spermatozoa) presented at ESHRE 2025. See Wouters et al., Human Reproduction, abstract O-228. These observations are not a product specification, not a claim of improved pregnancy rates, and not evidence of regulatory clearance. The investigators noted limits related to imaging and to how results generalise across samples.
Belgium
UZ Brussel
Involved in development, evaluation, and operational use of the sperm-search workflow.
India
Reliance Hospital
International deployment experience with T’EASY outside the development laboratory.
T’EASY is being commercialized and is not yet certified as a medical device. Availability, intended use, and permitted deployment conditions depend on the destination market. Embryologists remain responsible for review and for clinical decisions.